THE EFFECTIVENESS OF CERTAIN MAGNESIUM SALTS IN NEPHROLITHIASIS CAUSED BY THE USE OF SODIUM OXALATE AND CELECOXIB


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study was aimed to evaluation the effect of different magnesium salts and their combinations with pyridoxine on a course of calciumoxalate nephrolithiasis, which was modeled by adding the sodium oxalate (3% of weight of the diet) and selective cyclooxygenase-2 inhibitor celecoxib at a dose 100 mg/kg body weight to a diet for 4 weeks. Starting from the 2nd week of the experiment, the animals had received one of the following compounds: magnesium L-aspartate, magnesium chloride, and their combination with vitamin B 6; magnesium sulfate and Magne B 6 (magnesium lactate and vitamin B 6) as comparators. 28 days after the start of the experiment, disorders progressed in the group receiving only celecoxib and oxalate-rich diet: the urine level of oxalate increased by 171% (р<0,0001), crystalluria had increased (up to 105 crystals in 10 μml of urinary sediment, р<0,0001), creatinine clearance decreased by 29%, compared to control (р=0,087). Increasing calcium/magnesium and oxalate/creatinine ratios in urine by 16 and 189%, respectively, was observed. In the renal parenchyma of animals treated with sodium oxalate and celebrex, calcifications with a volume fraction of 4% were identified, whereas these changes were absent in intact animals. According to the degree of correction of hyperoxaluria and elimination of calcium oxalate crystals, investigated salts showed similar efficacy, with the exception of magnesium sulfate, which less contributed the compensation of abnormalities in kidney and urinary. According to the data of morphological study, the volume fraction of calcifications was lowest in the groups receiving magnesium L-aspartate and Magne B 6.

Full Text

Restricted Access

References

  1. Лопаткин Н.А., Мартов А.Г. Состояние и перспективы развития урологической помощи в Российской Федерации. Матер. Х Российского съезда урологов. М., 2002. Официальный сайт Российского общества урологов. [Электронный ресурс]. Режим доступа: http://www.uror2r2line.ru/society/plenum/sjesd1.php3
  2. Спасов А.А., Иежица И.Н., Харитонова М.В., Кравченко М.С., Снигур Г.Л. Роль алиментарного дефицита магния в формировании нефролитиаза у крыс и его коррекция солями магния. Вопр. пит. 2008; 77(6): 62-71.
  3. Бакумов П.А., Лялюев А.М., Барканова О.Н. Коррекция дефицита магния у больных оксалурией, оксалатным нефролитиазом. Микроэлементы в медицине. 2004;5(4):5.
  4. Kohri K., Garside J., Blacklock N.J. The role of magnesium in calcium oxalate urolithiasis. Br. J. Urol. 1988; 61(2): 107-115.
  5. Спасов А.А., Иежица И.Н., Харитонова М.В. и др. Экспериментальное обоснование эффективности солей магния в коррекции экспериментального кальций-фосфатного нефролитиаза. Нефрология. 2008; 12(3): 72-78.
  6. Prien E.L., Gershoff S.N. Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi. J. Urol. (Baltimore) 1974;112: 509-512.
  7. Khan S.R., Shevock P.N., Hackett R.L. Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. J. Urol. (Baltimore) 1993; 149: 412-416.
  8. Jeong B.C., Park M.Y., Kwak C. et al. An animal model of calcium oxalate urolithiasis based on a cyclooxygenase 2 selective inhibitor. Urol Res. 2005;33(6): 453-459.
  9. Сивориновский Г.А. К методике определения щавелевой кислоты в моче. Лабораторное дело. 1969; 7: 401-404.
  10. Меньшиков В.В. Лабораторные методы исследования в клинике: справочник / В.В. Меньшиков, Л.Н. Делекторская, Р.М. Золотнинская. М.: Медицина, 1987:266-267.
  11. Allegra A., Corica F., Ientile R. et al. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplantant recipients during cyclosporine and/or azathioprine treatment. Magnes. Res. 1998; 11(1): 11-18.
  12. Garsia-Rodrigeuez M.B., Perez-Garsia C.C., Rios-Granja M.A. et al. Renal handling of calcium and phosphorus in experimental renal hyperparathyroidism in dogs. Vet. Res. 2003; 34: 379-387.
  13. Рыбина И.Л., Вощула В.И. Оценка роли метаболизма оксалата в этиопатогенезе мочекаменной болезни. БМЖ 2006; (1):15.
  14. Durlach J., Guiet-Bara A., Pagès N. et al. Magnesium chloride or magnesium sulfate: a genuine question. Magnes. Res. 2005; 18(3): 187-192.
  15. Спасов А.А., Петров В.И., Иежица И.Н. и др. Сравнительная фармакологическая активность органических и неорганических солей магния в условиях системной алиментарной гипомагнезиемии. Вестник Российской академии медицинских наук. 2010; (2): 29-37.
  16. Dobson D.M., Finalayson B. Oxalate transport from plasma to intestinal lumen in the rat. Surg. Forum. 1973; 24: 540-542.
  17. Sarica K., Erbagci A., Yagci F. et al. Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria. Urol. Res. 2004; 32 (4): 271-277.
  18. Kwak C., Kim H.K., Kim E.C. et al. Urinary oxalate levels and the enteric bacterium Oxalobacter formigenes in patients with calcium oxalate urolithiasis. Eur. Urol. 2003; 44(4): 475-481.
  19. Спасов А.А., Иежица И.Н., Кравченко М.С. и др. Влияние солей магния на течение экспериментального кальций-оксалатного уролитиаза. Урология. 2011; (2): 23-29.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies